Supplement-To-Drug Applications Look Like The Next Wave To Some Experts
This article was originally published in The Tan Sheet
Executive Summary
FDA's dietary supplement good manufacturing practices, while imposed to help assure safe nutritionals reach the market, are creating costs that could drive more firms to file new drug applications for natural products, according to a pair of regulatory experts
You may also be interested in...
ChromaDex Looks To Pharma Model For Commercializing Supplement Research
Nutritional ingredient developer ChromaDex is employing a pharma-style business model to expand its R&D into finished dietary supplements – with a long-term eye on pharmaceutical products. The firm’s recent hire of CEO Jeffrey Himmel was a significant step into the consumer products arena.
ChromaDex Looks To Pharma Model For Commercializing Supplement Research
Nutritional ingredient developer ChromaDex is employing a pharma-style business model to expand its R&D into finished dietary supplements – with a long-term eye on pharmaceutical products. The firm’s recent hire of CEO Jeffrey Himmel was a significant step into the consumer products arena.
Technical Hurdles, Commercial Limits Complicate Supplement-To-Drug Moves
Firms should investigate regulatory hurdles and gauge the commercial appeal of a finished product before moving dietary supplement ingredients into the pharmaceutical realm, say manufacturing and testing consultants